DalCor Pharmaceuticals today announced that the independent dal-GenE Data and Safety Monitoring Board (DSMB) recommends the dal-GenE pivotal outcomes trial should continue as planned with no modifications. The post DalCor announces dal-GenE trial continues with final data expected in the first half of 2021 appeared first on DalCor Pharmaceuticals .
Discovery
Learnings
- auto_storiesStories
- categoryAreas
- helpFAQ
- forumConversations
- descriptionPapers
- mailNewsletters
- video_libraryVideos
- timelineTimeline
Guidance
- codeTechnology of APIs
- business_centerBusiness of APIs
- campaignEvangelism of APIs
- gavelGovernance of APIs
- historyHistory of APIs
- account_balancePolitics of APIs
Toolbox
- domainProviders
- apiAPIs
- cloudSolutions
- buildTools
- verifiedStandards
- gavelRegulations
- horizontal_ruleHeaders
- layersOverlays
- extensionExtensions
- schemaSchema
- policyPolicies
- ruleRules